首页> 外文期刊>International Journal of Molecular Sciences >The Epidermal Growth Factor Receptor and Its Ligands in Cardiovascular Disease
【24h】

The Epidermal Growth Factor Receptor and Its Ligands in Cardiovascular Disease

机译:心血管疾病中的表皮生长因子受体及其配体

获取原文
           

摘要

The epidermal growth factor receptor (EGFR) family and its ligands serve as a switchboard for the regulation of multiple cellular processes. While it is clear that EGFR activity is essential for normal cardiac development, its function in the vasculature and its role in cardiovascular disease are only beginning to be elucidated. In the blood vessel, endothelial cells and smooth muscle cells are both a source and a target of EGF-like ligands. Activation of EGFR has been implicated in blood pressure regulation, endothelial dysfunction, neointimal hyperplasia, atherogenesis, and cardiac remodeling. Furthermore, increased circulating EGF-like ligands may mediate accelerated vascular disease associated with chronic inflammation. Although EGFR inhibitors are currently being used clinically for the treatment of cancer, additional studies are necessary to determine whether abrogation of EGFR signaling is a potential strategy for the treatment of cardiovascular disease.
机译:表皮生长因子受体(EGFR)家族及其配体可作为调节多种细胞过程的配电盘。尽管很明显,EGFR的活性对于正常的心脏发育至关重要,但它在脉管系统中的功能及其在心血管疾病中的作用才刚刚被阐明。在血管中,内皮细胞和平滑肌细胞都是EGF样配体的来源和目标。 EGFR的激活与血压调节,内皮功能障碍,新内膜增生,动脉粥样硬化和心脏重塑有关。此外,循环中类似EGF的配体增加可能会介导与慢性炎症相关的加速血管疾病。尽管目前在临床上将EGFR抑制剂用于临床治疗癌症,但仍需要进行更多的研究来确定废除EGFR信号传导是否是治疗心血管疾病的潜在策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号